Ariane Willems

Ariane Willems

Auto-generated profile, based on publicly available information

Ariane Willems

Pediatric Intensive Care Unit, Leiden University Medical Center (LUMC), Postbus 9600, 2300 RC Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2020 in Perfusion
Verified
Journal Article
Open access
PDF file
AWAriane Willems
Ariane Willems
PRPeter P Roeleveld
Peter P Roeleveld
SLSonia Labarinas
Sonia Labarinas
JCJohn Cyrus
John Cyrus
JMJennifer A Muszynski
Jennifer A Muszynski
OKOliver Karam
Oliver Karam
The purpose was to compare time-based vs anti-Xa-based anticoagulation strategies in patients on ECMO. We conducted a systematic review and meta-analysis using multiple electronic databases and included studies from inception to July 19, 2019. The proportion of bleeding, thrombosis, and mortality were evaluated. Twenty-six studies (2,086 patients) were included. Bleeding occurred in 34.2% (95%CI 25.1;43.9) of the patients with anti-Xa-based versus 41.6% (95%CI 24.9;59.4) of the patients with time-based anticoagulation strategies. Thrombosis occurred in 32.6% (95%CI 19.1;47.7) of the patients with anti-Xa-based versus 38.4% (95%CI 22.2;56.1) of the patients with time-based anticoagulation strategies. And mortality rate was 35.4% (95%CI 28.9;42.1) of the patients with anti-Xa-based versus 42.9% (95%CI 36.9;48.9) of the patients with time-based anticoagulation strategies. Among the seven studies providing results from both anticoagulation strategies, significantly fewer bleeding events occurred in the anti-Xa-based anticoagulation strategy (adjusted OR 0.49 (95%CI 0.32;0.74), p < 0.001) and a significantly lower mortality rate (adjusted OR 0.61 (95%CI 0.40;0.95), p = 0.03). There was no significant difference in thrombotic events (adjusted OR 0.91 (95%CI 0.56;1.49), p = 0.71). In these seven observational studies, only a small fraction of the patients were adults, and data were insufficient to analyze the effect of the type of ECMO. In this meta-analysis of observational studies of patients on ECMO, an anti-Xa-based anticoagulation strategy, when compared to a time-based strategy, was associated with fewer bleeding events and mortality rate, without an increase in thrombotic events.

3 July 2024 in Pediatric Critical Care Medicine
Verified
Journal Article
Open access
JMJennifer A. Md Muszynski
Jennifer A. Md Muszynski
MBMelania M. Bembea
Melania M. Bembea
AGAlison Paige Gehred
Alison Paige Gehred
ELElizabeth Mlis Lyman
Elizabeth Mlis Lyman
KCKatherine Do Cashen
Katherine Do Cashen
JTJun Md Teruya
Jun Md Teruya
OBJECTIVES: To identify and prioritize research questions for anticoagulation and hemostasis management of neonates and children supported with extracorporeal membrane oxygenation (ECMO) from the Pediatric ECMO Anticoagulation CollaborativE (PEACE) consensus. DATA SOURCES: Systematic review was performed using PubMed, EMBASE, and Cochrane Library (CENTRAL) databases from January 1988 to May 2021, followed by serial consensus conferences of international, interprofessional experts in the management of ECMO for critically ill neonates and children. STUDY SELECTION: The management of ECMO anticoagulation for critically ill neonates and children. DATA EXTRACTION: Within each of the eight subgroups, two authors reviewed all citations independently, with a third independent reviewer resolving any conflicts. DATA SYNTHESIS: Following the systematic review of MEDLINE, EMBASE, and Cochrane Library databases from January 1988 to May 2021, and the consensus process for clinical recommendations and consensus statements, PEACE panel experts constructed research priorities using the Child Health and Nutrition Research Initiative methodology. Twenty research topics were prioritized, falling within five domains (definitions and outcomes, therapeutics, anticoagulant monitoring, protocolized management, and impact of the ECMO circuit and its components on hemostasis). CONCLUSIONS: We present the research priorities identified by the PEACE expert panel after a systematic review of existing evidence informing clinical care of neonates and children managed with ECMO. More research is required within the five identified domains to ultimately inform and improve the care of this vulnerable population.

1 June 2019 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
AWAriane Willems
Ariane Willems
PPPhilippe Patte
Philippe Patte
FGFrançoise De Groote
Françoise De Groote
PLPhilippe Van der Linden
Philippe Van der Linden

Verified
Journal Article
Open access
PDF file
VLVictorien Anna Christina Luppes
Victorien Anna Christina Luppes
AWAriane Willems
Ariane Willems
Mark HazekampMark Hazekamp
Mark Hazekamp
NBNico Blom
Nico Blom
DHDerk Jan Ten Harkel
Derk Jan Ten Harkel
Background: Fluid overload (FO) is known to occur frequently after pediatric cardiac surgery and is associated with morbidity and mortality. Fontan patients are at risk to develop FO due to their critical fluid balance. Furthermore, they need an adequate preload in order to maintain adequate cardiac output. This study aimed to identify FO in patients undergoing Fontan completion and the impact of FO on pediatric intensive care unit (PICU) length of stay (LOS) and cardiac events, defined as death, cardiac re-surgery or PICU re-hospitalization during follow-up. Methods: In this retrospective single center study, the presence of FO was assessed in 43 consecutive children undergoing Fontan completion. Results: Patients with more than 5% maximum FO had an extended PICU LOS (3.9 [2.9–6.9] vs. 1.9 [1.0–2.6] days; p < 0.001) and an increased length of mechanical ventilation (21 [9–121] vs. 6 [5–10] h; p = 0.001). Regression analysis demonstrated that an increase of 1% maximum FO was associated with a prolonged PICU LOS of 13% (95% CI 1.042–1.227; p = 0.004). Furthermore, patients with FO were at higher risk to develop cardiac events. Conclusions: FO is associated with short-term and long-term complications. Further studies are needed to determine the impact of FO on the outcome in this specific population.

1 September 2023 in Minerva Anestesiologica
Verified
Journal Article
Closed access
AWAriane Willems
Ariane Willems
RHRenaud Havaux
Renaud Havaux
DSDenis Schmartz
Denis Schmartz
JFJean-François Fils
Jean-François Fils
FPFrançoise DE Pooter
Françoise DE Pooter
PLPhilippe VAN DER Linden
Philippe VAN DER Linden
Article: The choice of perioperative inotropic support impacts the outcome of small infants undergoing complex cardiac surgery: an observational study - Minerva Anestesiologica 2023 September;89(9):753-61 - Minerva Medica - Journals

6 May 2021 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
AWAriane Willems
Ariane Willems
FGFrançoise De Groote
Françoise De Groote
DSDenis Schmartz
Denis Schmartz
JFJean-François Fils
Jean-François Fils
PLPhilippe Van der Linden
Philippe Van der Linden
BACKGROUND Unbalanced fluid solutions cause metabolic acidosis and could be associated with impaired coagulation and increased blood loss. OBJECTIVE To investigate whether the use of a balanced colloid compared with a saline colloid for peri-operative fluid therapy in children undergoing cardiac surgery is associated with decreased blood loss and exposure to blood products. DESIGN Double-blinded randomised controlled trial. SETTING Tertiary children's hospital from 2013 to 2016. PATIENTS Children older than 29 days and younger than 3 years admitted for cardiac surgery with cardiopulmonary bypass (CPB). Exclusion criteria were emergency cardiac surgery, moribund (American Society of Anesthesiologists 5), Jehovah's witnesses, coagulopathy, renal failure, liver injury, intracranial haemorrhage and electrolyte disturbances. From the 128 patients eligible, 88 were included in the study. INTERVENTION Random assignment of patients to either a saline colloid (6% hydroxyethyl starch 130/0.4 in 0.9% NaCl) or a balanced-electrolyte colloid (6% hydroxyethyl starch 130/0.4 in an isotonic solution) for CPB priming and intra- and postoperative fluid therapy during the first postoperative 48 h. MAIN OUTCOME MEASURE The primary outcome measure was calculated blood loss until the third postoperative day (POD3). RESULTS A total of 44 patients were included in each study arm. Calculated blood loss at POD3 was not significantly different between the groups (saline colloid 19.9 [IQR 13.8 to 26.1] ml kg−1 versus balanced colloid 15.9 [IQR 9.0 to 25.3 ml kg−1], P = 0.409). Secondary outcomes related to bleeding, exposure to blood products and coagulation were not different between groups. There was also no difference in length of mechanical ventilation, intensive care and hospital length of stay between groups. CONCLUSION The use of a balanced colloid for peri-operative fluid therapy compared with a saline one is not associated with decreased blood loss or exposure to blood products. TRIAL REGISTRATION EudraCT identifier: 2012-006034-17 and ClinicalTrial.gov identifier: NCT02584868.